AR065179A1 - Progesterona para el tratamiento o prevencion del parto prematuro espontaneo - Google Patents

Progesterona para el tratamiento o prevencion del parto prematuro espontaneo

Info

Publication number
AR065179A1
AR065179A1 ARP080100476A ARP080100476A AR065179A1 AR 065179 A1 AR065179 A1 AR 065179A1 AR P080100476 A ARP080100476 A AR P080100476A AR P080100476 A ARP080100476 A AR P080100476A AR 065179 A1 AR065179 A1 AR 065179A1
Authority
AR
Argentina
Prior art keywords
progesterone
treatment
prevention
premature birth
spontaneous premature
Prior art date
Application number
ARP080100476A
Other languages
English (en)
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065179(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of AR065179A1 publication Critical patent/AR065179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar o prevenir el parto prematuro espontáneo en mujeres embarazadas y mejorar la morbilidad y mortalidad neonatal. El método incluye administrar a una mujer embarazada que lo requiere una cantidad efectiva de progesterona suficiente para prolongar la gestacion al minimizar el acortamiento o borramiento de su cuello uterino. Se ha demostrado clínicamente que el tratamiento y profilaxis con progesterona en una mujer embarazada que tiene síntomas de cuello uterino corto aumenta la salud neonatal.
ARP080100476A 2007-02-06 2008-02-05 Progesterona para el tratamiento o prevencion del parto prematuro espontaneo AR065179A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19
US12/024,756 US8828981B2 (en) 2007-02-06 2008-02-01 Progesterone for the treatment or prevention of spontaneous preterm birth

Publications (1)

Publication Number Publication Date
AR065179A1 true AR065179A1 (es) 2009-05-20

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100476A AR065179A1 (es) 2007-02-06 2008-02-05 Progesterona para el tratamiento o prevencion del parto prematuro espontaneo

Country Status (24)

Country Link
US (2) US8828981B2 (es)
EP (1) EP2117554B1 (es)
JP (2) JP5580601B2 (es)
KR (1) KR101546101B1 (es)
AR (1) AR065179A1 (es)
AU (1) AU2008212724A1 (es)
BR (1) BRPI0807203A2 (es)
CA (1) CA2677354C (es)
CL (1) CL2008000375A1 (es)
CO (1) CO6220941A2 (es)
CR (1) CR10985A (es)
ES (1) ES2596803T3 (es)
GE (1) GEP20135727B (es)
HK (1) HK1136975A1 (es)
IL (1) IL200272A (es)
MA (1) MA31200B1 (es)
ME (1) ME00930B (es)
MX (1) MX2009008409A (es)
MY (1) MY184866A (es)
NZ (1) NZ579114A (es)
PE (1) PE20081738A1 (es)
RU (1) RU2524617C2 (es)
TW (1) TWI471135B (es)
WO (1) WO2008096122A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533915C (en) 2002-08-13 2020-09-22 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
SI2359807T1 (sl) 2008-02-04 2017-10-30 Ferring B.V. Monolitni intravaginalni obroč, ki vsebuje progesteron ter postopki za njegovo izdelavo in uporabo
WO2010034779A2 (en) 2008-09-24 2010-04-01 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
CA2789238C (en) * 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
CA2813433C (en) * 2010-10-27 2019-08-20 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102012009057A1 (de) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotationspessar mit zusätzlicher Wirkstoffkomponente
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014107373A1 (en) * 2013-01-02 2014-07-10 N-Dia, Inc. Methods for predicting time-to-delivery in pregnant women
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DK2982352T3 (en) * 2014-06-28 2018-11-26 Laboratorios Andromaco S A CERVICALLY PESSAR CONTAINING PROGESTERON FOR EXTENDED, LONG AND CONTINUOUS RELEASE USED TO PREVENT EARLY BIRTHS
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
KR101726488B1 (ko) 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
US11029318B2 (en) * 2015-08-28 2021-06-08 Kypha, Inc. Methods for predicting and treating patients with increased risk of adverse pregnancy outcome
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017200987A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
JP2018140172A (ja) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ データ収集装置及びデータ収集方法
US11207509B2 (en) 2017-06-15 2021-12-28 Wiesman Holdings, LLC Method and device for delivery of a solution into a body orifice
RU2657772C1 (ru) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Способ профилактики гестационных осложнений у беременных с эпилепсией
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
AU2018357888A1 (en) * 2017-10-30 2020-05-28 Carmentix Pte. Ltd. Biomarkers of preterm birth
RU2692932C2 (ru) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) БИОКАТАЛИЗАТОР ДЛЯ ПОЛУЧЕНИЯ 11α-АЦЕТОКСИПРОГЕСТЕРОНА
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (ja) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 新生児期～小児期発症の脳小血管病又はその保因者の検出方法
KR102157438B1 (ko) * 2019-04-16 2020-09-21 고려대학교 산학협력단 조산 진단 방법 및 키트
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation
WO2021068239A1 (zh) 2019-10-12 2021-04-15 国家卫生健康委科学技术研究所 用于黄体支持的阴道缓释给药系统及其制备方法与应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR102482468B1 (ko) * 2020-08-11 2022-12-28 연세대학교 산학협력단 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (de) 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
HUP9800826A3 (en) 1995-03-14 1998-08-28 Schering Ag Use of nitric oxide donors or nitric oxide inhibitors for preparing medicaments for regulating cervical dilatation and extensibility
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) * 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
AU5683900A (en) 1999-06-21 2001-01-09 Columbia Laboratories (Bermuda) Limited Programming ovulation
US6375970B1 (en) * 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
JP2005503389A (ja) 2001-08-31 2005-02-03 シエーリング オサケユイチア 薬物送達システム
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
WO2004071427A2 (en) 2003-02-06 2004-08-26 Adeza Biomedical Corporation Screening and treatment methods for prevention of preterm delivery
TW200626161A (en) 2004-10-07 2006-08-01 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
EA015155B1 (ru) 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
MY184866A (en) 2021-04-28
US20090264395A1 (en) 2009-10-22
CL2008000375A1 (es) 2008-05-30
TW200902030A (en) 2009-01-16
IL200272A0 (en) 2010-04-29
MA31200B1 (fr) 2010-02-01
RU2009133315A (ru) 2011-03-20
JP2010518058A (ja) 2010-05-27
EP2117554B1 (en) 2016-07-13
HK1136975A1 (zh) 2010-07-16
PE20081738A1 (es) 2008-11-20
US20080188829A1 (en) 2008-08-07
RU2524617C2 (ru) 2014-07-27
WO2008096122A2 (en) 2008-08-14
EP2117554A2 (en) 2009-11-18
JP5580601B2 (ja) 2014-08-27
CR10985A (es) 2009-10-23
US7884093B2 (en) 2011-02-08
ES2596803T3 (es) 2017-01-12
WO2008096122A3 (en) 2009-02-26
CO6220941A2 (es) 2010-11-19
JP2014058529A (ja) 2014-04-03
GEP20135727B (en) 2013-01-25
NZ579114A (en) 2012-07-27
IL200272A (en) 2014-02-27
KR101546101B1 (ko) 2015-08-20
ME00930B (me) 2012-03-20
CA2677354C (en) 2015-07-07
TWI471135B (zh) 2015-02-01
BRPI0807203A2 (pt) 2014-07-22
MX2009008409A (es) 2009-09-16
AU2008212724A1 (en) 2008-08-14
KR20090123875A (ko) 2009-12-02
US8828981B2 (en) 2014-09-09
CA2677354A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
AR065179A1 (es) Progesterona para el tratamiento o prevencion del parto prematuro espontaneo
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
BRPI0517799A (pt) composição para facilitar o parto humano
ECSP088390A (es) Método para la anticoncepción hormonal preventiva bajo demanda
ECSP13012650A (es) Métodos y composiciones para tratar diarrea asociada con vih
American College of Obstetricians and Gynecologists ACOG Committee opinion no. 550: maternal-fetal surgery for myelomeningocele
MY181349A (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
BR112014026340A2 (pt) sandália para hálux valgo
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
ECSP12011629A (es) Fulvestrant en una dosis de 500 mg para el tratamiento del cáncer de mama avanzado
UA101474C2 (ru) Применение прогестерона для производства лекарственного средства
TN2015000197A1 (en) Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
MX2015014222A (es) Composiciones farmaceuticas comprendiendo kisspeptina o sus derivados y metodo de preparacion de dichas composiciones.
AR057755A1 (es) Metodo para tratar mamiferos placentarios parturientos con el fin de reducir el agotamiento materno y/o uterino
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido
UA41294U (ru) Способ лечения синдрома ашермана у женщин репродуктивного возраста
Mahto et al. Management of Dystocia due to Uterine Torsion in a Doe
Alkareem et al. Comparison of Different Medical Treatment of Missed Abortion
市田美保 et al. No increase in breast cancer risk in Japanese women taking oral contraceptives: A case-control study investigating reproductive, menstrual and familial risk factors for breast cancer.
MD3645G2 (ro) Metodă de tratament al hemoragiilor uterine hipotonice postnatale
MD335Z (ro) Metodă de pregătire a colului uterin pentru inducerea travaliului la gestantele cu sarcină prolongată
AR076016A1 (es) Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure